Biotechnology

BIOTEST BIOTECH

BIOTEST BIOTECH released FY2026 Q1 earnings on April 24 Pre-Market (BJT), actual revenue CNY 89.38 M, actual EPS CNY -0.07

BIOTEST BIOTECH FY2026 Q1 Earnings Release on April 25 Pre-Market (BJT)

BIOTEST BIOTECH FY2025 Annual Earnings Release on April 25, 2026 Pre-Market (BJT)

BIOTEST BIOTECH released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 139.94 M, actual EPS CNY 0.2636

BIOTEST BIOTECH released FY2025 earnings on February 27 Pre-Market (BJT), actual revenue CNY 448.01 M, actual EPS CNY 0.34

BIOTEST BIOTECH released FY2025 9 Months Earnings on October 29 After-Market BJT, actual revenue CNY 308.07 M, actual EPS CNY 0.1556

BIOTEST BIOTECH released FY2025 Q3 earnings on October 29 After-Market BJT, actual revenue CNY 104.79 M, actual EPS CNY 0.0803

BIOTEST BIOTECH FY2025 Q3 Earnings Release on October 30, 2025, After-Market (BJT)

BIOTEST BIOTECH released FY2025 Q2 earnings on August 28 During-Market (BJT), actual revenue CNY 115.39 M, actual EPS CNY 0.0182

BIOTEST BIOTECH released FY2025 Semi-Annual Earnings on August 28 During-Market (BJT), actual revenue CNY 203.28 M, actual EPS CNY 0.07

BIOTEST BIOTECH FY2025 Semi-Annual Earnings Release on August 29, 2025 (BJT)

Biotop Biotech Executives Reduce Shares by 560,000

First Closed-loop Spinal Cord Neural Interface Surgery in China Successful

Botuo Biotech's Q1 2025 Revenue and Net Profit Down Year-over-Year

BIOTEST BIOTECH released FY2025 Q1 earnings on April 25 After-Market BJT, actual revenue CNY 87.89 M, actual EPS CNY 0.0571

BIOTEST BIOTECH to Release FY2025 Q1 Earnings on April 26 After-Market BJT

BIOTEST BIOTECH to Release FY2024 Annual Earnings Report on April 26, 2025 (BJT)

BIOTEST BIOTECH released FY2024 Q4 earnings on February 26 (BJT), actual revenue CNY 170.62 M, actual EPS CNY 0.5322

BIOTEST BIOTECH released FY2024 earnings on February 26, 2025 (BJT) with actual revenue of CNY 559.4 M and EPS of CNY 1.15

Botao Bio Expects 2024 Net Profit to Increase by 59.47% Year-on-Year

688626

159998

002555

688767

512720

Brain-computer interface technology is set for commercial expansion, with large-scale applications expected by 2026. The A-share market has fewer than 30 related stocks, some indirectly involved through investments, while others are collaborating with academic institutions. Institutional research has noted progress in these stocks, with five being surveyed by over 100 institutions this year, including Xiangyu Medical, Aipeng Medical, Entropy Technology, Botuo Biological, and 37 Interactive Entertainment.

CoinLive

Xiangyu Medical

Tianhong CSI Computer Theme ETF

SANQI HUYU

Guotai CSI Computer Theme ETF

AI TRENDS | Brain-Computer Interface Technology Set for Commercial Expansion by 2026

300753

301330

Since the beginning of this year, the brain-computer interface industry has made significant progress. The world's first invasive brain-computer interface medical device was approved for market launch on March 13 and completed the medical insurance coding on March 15, marking the industry's entry into the clinical application stage. According to data from Data Treasure, 12 brain-computer interface concept stocks have received institutional research, among which 5 stocks have more than 110 institutions participating in the research, including Xiangyu Medical, APON, ZKTECO, BIOTEST BIOTECH, and 37 Interactive Entertainment

36Kr

APON

ZKTECO

Brain-computer interfaces are becoming a reality, with over 100 institutions researching 5 concept stocks this year

301293

The A-share brain-computer interface concept is actively defying the trend, with BIOTEST BIOTECH rising over 10%, and Meihao Medical, Sanbo, APON, and Xiangyu Medical following suit

Wallstreetcn

Sanbo

603598

688068

36Kr learned that the three major indices of A-shares collectively closed higher, with the Shanghai Composite Index rising 1.38% to return to 4,000 points, the Shenzhen Component Index rising 2.24%, and the ChiNext Index rising 2.85%; the semiconductor, cultural media, and biotechnology sectors led the gains, with Dongwei Semiconductor, Inly, and BIOTEST BIOTECH hitting the daily limit, and Hotgen rising over 8%; the energy, catering and tourism, and paper-making sectors saw the largest declines, with China National Offshore Oil Corporation falling over 3%, Guilin Tourism dropping over 2%, and Sun Paper falling over 1%

Inly

Hotgen

The three major A-share indices collectively closed higher, with the Shanghai Composite Index returning to 4,000 points

688273

In a recent earnings briefing, several A-share listed companies, including Xiangyu Medical, MEDLANDER, BIOTEST BIOTECH, and ZKTECO, disclosed the latest developments in brain-computer interface technology. Some companies expect to achieve revenue within the year, launch new products, and seize development opportunities through investment layouts. In the second half of the year, relevant companies will accelerate investment and product implementation, and local policies will also support commercialization, driving the brain-computer interface industry into a new phase

Zhitong

MEDLANDER

Multiple A-share companies reveal progress and product updates in brain-computer interface technology

According to the Zhitong Finance APP, BIOTEST BIOTECH disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 203 million yuan, a year-on-year decrease of 23.91%; net profit attributable to the parent company was 12.4 million yuan, a year-on-year decrease of 82.82%; net profit excluding non-recurring items was 6.83 million yuan, a year-on-year decrease of 90.25%; basic earnings per share were 0.07 yuan

BIOTEST BIOTECH released its semi-annual performance, with a net profit attributable to the parent company of 12.4 million yuan, a year-on-year decrease of 82.82%

BIOTEST BIOTECH announced that as of the date of this announcement, the actual controller, Xiu Ping, holds 24.9536 million shares of the company, accounting for 16.71%. Due to personal funding needs, he plans to reduce his holdings through centralized bidding by no more than 1.4933 million shares and through block trading by no more than 2.9867 million shares, totaling no more than 4.48 million shares, which is no more than 3%

BIOTEST BIOTECH: Xu Ping plans to reduce her holdings by 3% starting in September

According to the Zhitong Finance APP, BIOTEST BIOTECH announced that the share reduction plan of the company's director and senior management Gao Hongmei has been completed, with a total of 560,000 shares sold through centralized bidding, accounting for 0.5250% of the company's total share capital

Gao Hongmei, a director of BIOTEST BIOTECH, completed a reduction in holdings, with a total reduction of 560,000 shares

China's first closed-loop spinal cord nerve interface implantation surgery was successfully completed recently, attracting significant attention. The surgery was jointly performed by the Second Affiliated Hospital of Zhejiang University School of Medicine and the Nanhu Brain-Machine Intersection Research Institute. On the 20th, BIOTEST BIOTECH announced that it had invested in Qingshi Yongjun through BoTai ZhiTou and acquired a 5% equity stake. The latter was founded by the invasive brain-machine interface team from Zhejiang University and is the first technology transfer enterprise of the Nanhu Brain-Machine Intersection Research Institute

BIOTEST BIOTECH: Wholly-owned subsidiary Botai Zhito strategically invests in Zhejiang University Brain-Machine Interface Achievement Transformation Project

BIOTEST BIOTECH(688767.SH)